RNA-based therapeutics have shown great promise in treating a broad spectrum of
diseases through various mechanisms including knockdown of pathological genes …

Five small interfering RNA (siRNA)-based therapeutics have been approved by the Food
and Drug Administration (FDA), namely patisiran, givosiran, lumasiran, inclisiran, and …

Magnetic nanoparticles (NPs) are emerging as an important class of biomedical functional
nanomaterials in areas such as hyperthermia, drug release, tissue engineering, theranostic …

Targeted delivery combined with controlled drug release has a pivotal role in the future of
personalized medicine. This review covers the principles, advantages, and drawbacks of …

With the recent FDA approval of the first siRNA‐derived therapeutic, RNA interference
(RNAi)‐mediated gene therapy is undergoing a transition from research to the clinical …

Genetic engineering of plants has enhanced crop productivity in the face of climate change
and a growing global population by conferring desirable genetic traits to agricultural crops …

Cancer is the second worldwide cause of death, exceeded only by cardiovascular diseases.
It is characterized by uncontrolled cell proliferation and an absence of cell death that, except …

Cancer is the second most common cause of death in the United States, trailing only heart
disease in incidence. Despite significant worldwide investment in research, cancer remains …

RNA interference (RNAi) is a unique treatment approach used to decrease a disease's
excessive gene expression, including cancer. SiRNAs may find and destroy homologous …

In medicine, nanotechnology has sparked a rapidly growing interest as it promises to solve a
number of issues associated with conventional therapeutic agents, including their poor …